



Directions for use
Read carefully!

Composition

100 ml solution contains:
Potassium Chloride

Excipient
Water for Injections
1 ml contains 2 mmol potassium and 2 mmol chloride.

Pharmaceutical form

Concentrate for solution for infusion

Pharmaco-therapeutic group

Electrolyte replacement solutions

Indications

States of potassium deficiency, especially if accompanied by alkali excess and decreased chloride concentration in the blood (hypochloraemic alkalosis).

Contraindications

B. Braun Sterile Potassium Chloride Concentrate 14.9% must not be administered when there are
- an elevated potassium level (hyperkalaemia)
- an elevated chloride level (hyperchloraemia)
- disorders that are frequently associated with hyperkalaemia such as dehydration, reduced renal excretion, Addison's disease, Adynamia episodica hereditaria (Gamstorp's syndrome), sickle cell anaemia.

Special warnings and precautions for use

B. Braun Sterile Potassium Chloride Concentrate 14.9% should only be administered with caution when there is
- cardiac decompensation
- simultaneous treatment with potassium-saving diuretics, aldosterone antagonists, ACE inhibitors or potentially nephrotoxic medicaments (nonsteroid anti-inflammatories etc.).

The administration of potassium-containing infusions must be discontinued if there are signs of renal insufficiency.

There are typical changes in the ECG when the potassium balance is disturbed (hypo- or hyperkalaemia).

However, there is no linear relationship between the ECG changes and the concentration of potassium in the blood.

Clinical monitoring should include checks of the serum ionogram and the acid-base balance.

It must be made absolutely sure that the solution is administered intravenously, because paravenous administration may cause tissue necrosis.

Interactions

An increase in the extracellular potassium concentration reduces the effect of cardiac glycosides, a reduction increases the arrhythmogenic effect of cardiac glycosides.

14.9 g

B. Braun Sterile
Potassium Chloride
Concentrate 14.9%

Potassium saving diuretics, aldosterone antagonists, ACE inhibitors, nonsteroid anti-inflammatories and peripheral analgesics reduce the renal excretion of potassium. Severe hyperkalaemia can occur on simultaneous administration with potassium chloride.

Severe hyperkalaemia, with adverse effect on the heart rhythm, can also occur when suxamethonium and potassium are administered simultaneously.

Dosage

The dosage should be adjusted according to the analysis values of the serum ionogram and the acid base status.

The potassium deficit is calculated according to the following formula:

mmol potassium =
kg BW x 0.2 x 2 x (4.5 - current serum potassium [mmol/l]).
(Body weight x 0.2 represents the extracellular fluid volume.)

Maximum daily dose:
Not more than 2 - 3 mmol/kg BW/day

Maximum infusion rate:
Up to 20 mmol potassium per hour (corresponding to 0.3 mmol potassium/kg BW/hour) in adults.

Method of administration
Intravenously, only diluted as an additive to infusion solutions. The potassium concentration in the infusion solution must not exceed 40 mmol/l. Suitable vehicle solutions are e.g. 5% or 10% glucose solutions, isotonic sodium chloride solution, Compound Sodium Lactate solution, or complete electrolyte solutions.

B. Braun Sterile Potassium Chloride Concentrate 14.9% should only be added immediately before setting up the infusion and strictly aseptic technique should be observed.
The infusion bottle should then be gently shaken.

As a matter of principle, infusion pumps should be used for the infusion of potassium in the setting of correction therapy.

Overdose

Symptoms:
Overdose may cause hyperkalaemia, in particular in the presence of acidosis or kidney insufficiency.

The symptoms of hyperkalaemia are primarily cardiovascular disorders. There can be bradycardia, AV blockade and ventricular fibrillation and cardiac arrest. In the ECG there are high, sharp, symmetrical T-waves and, at very high potassium levels, broadening of the QRS complex. The vascular effects are hypotension and centralisation.

The neuromuscular symptoms encompass fatigue, weakness, states of confusion, heaviness of limbs, muscle twitching, paraesthesia, and ascending paralysis.

Plasma potassium concentrations greater than 6.5 mmol/l are dangerous, over 8 mmol/l often lethal.

Approval for Printing
B|BRAUN Melsungen AG

Approved for Printing ☐

Approved for Printing when corrected ☐

New draft required ☐

Date _____ Signature _____

Name in capital letters _____

schwarz

Dokument = 210 x 297 mm
DIN A4 – 2 Seiten

MY__104
Sterile Potassium Chloride
Concentrate 14.9%
GIF (MPc, MPw)
104/12608396/0117
Standort Penang



Font size: 9.5 pt.

G 1610134



Emergency treatment, antidotes:
The first measure is immediate stop of infusion. Further corrective measures include slow intravenous administration of 10% calcium gluconate, infusion of glucose together with insulin, increase of diuresis, oral or rectal administration of cation exchangers, correction of acidosis, if necessary.
In cases of severe intoxication haemodialysis may be necessary.

Undesirable effects
Administration of potassium chloride may be accompanied by nausea, acidosis, an elevated concentrations of chloride in the blood.
Too rapid infusion may lead to heart arrhythmia.

Note:
Patients are advised to inform their doctor or pharmacist if they notice any adverse effect not mentioned in this leaflet.

Usage during pregnancy
No adverse reaction has been reported. However, these injections should be given to a pregnant woman only if clearly needed.


Storage
The product should not be stored above the temperature stated on the label.

Shelf life
The product must not be used beyond the expiry date stated on the label.


Presentation
In plastic ampoules "Mini-Plasco®" and "Mini-Plasco® Connect" of 10 ml, 20 ml in box of 20's.

Instructions for use/handling
Only to be used if solution is clear and container undamaged.
The product is supplied in single-use containers. Unused portions must be discarded.

Mini-Plasco® Handling



Mini-Plasco® Connect Handling



B | BRAUN

Product registration holder
and manufactured by:
B. Braun Medical Industries Sdn. Bhd.
11900 Bayan Lepas, Penang, Malaysia.

